IPSEN CARES® patient support program can help you get access to your IQIRVO® prescription with the information and support you need.
To learn more about IPSEN CARES:
(866) 435-5677
Monday-Friday, 8:00 AM – 8:00 PM ET
Downloadable resources
IQIRVO Brochure
An informational brochure to help you understand the transformative power of IQIRVO
IQIRVO Discussion Guide
A guide to help you start the conversation about IQIRVO at your next appointment
Frequently Asked Questions
“Eye-ker-vo.”
IQIRVO is a once-daily oral pill used to treat primary biliary cholangitis (PBC) in adults.
IQIRVO is indicated for adults with primary biliary cholangitis (PBC). IQIRVO is an add-on treatment, meaning it is taken alongside ursodiol. However, in people who are unable to take ursodiol, IQIRVO can be taken alone.
Talk to your doctor to see if IQIRVO is right for you.
IQIRVO is thought to act on multiple targets in the liver. Two of these targets are PPAR alpha and PPAR delta.* In the liver, PPAR alpha and PPAR delta help control liver inflammation and levels of certain substances, like bile acids.
*This information is based on animal studies, and the way IQIRVO works is not fully understood.
IQIRVO is taken once daily as an oral pill.
IQIRVO can be taken with or without food.
See your doctor for more specific dosing instructions and regimens.
IQIRVO should be stored in its original packaging at room temperature. Keep IQIRVO out of reach of children.
Talk to your doctor about starting IQIRVO. IPSEN CARES patient support program can help you get access to your IQIRVO prescription with the information and support you need. To learn more about IPSEN CARES, visit www.ipsencares.com.
Some people taking IQIRVO may be eligible for a $0 copay.a Learn more about financial assistance at www.ipsencares.com.
Learn about accessing IQIRVO at www.ipsencares.com.
Glossary of terms
Alkaline phosphatase, an enzyme found in the liver. High levels of ALP in the blood are associated with liver diseases like PBC. This marker can be used to track response to treatment.
A component of bile. High levels of bilirubin indicate advanced disease in PBC. Regular measurement of bilirubin can be used to track PBC disease progression and response to treatment.
Primary biliary cholangitis, a chronic autoimmune liver disease.
Peroxisome proliferator-activated receptor.
Ursodeoxycholic acid, also known as ursodiol. It is the standard first treatment option for people with PBC.
The upper limit of normal, or ULN, is the high end of a normal range for a lab value. When assessing a patient's response to treatment for PBC, the definition of response may include an ALP level in relation to the ULN (for example, an ALP level of 1.67 x ULN).
a Patient Eligibility & Terms and Conditions: Patients are not eligible for copay assistance through IPSEN CARES if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TRICARE (collectively, “Government Programs”), or where prohibited by law. Patients must be United States residents (including its territories) and enrolled in IPSEN CARES to receive copay program benefits. Patients receiving assistance through another assistance program or foundation, free trial, or other similar offer or program, are not eligible for the copay assistance program during the current enrollment year. An annual calendar year maximum copay benefit applies. Patients may remain enrolled in copay assistance as long as eligibility criteria is met. Patients or guardians are responsible for reporting receipt of copay savings benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled through the program, as may be required. Additionally, patients or guardians may not submit any benefit provided by this program for reimbursement through a Flexible Spending Account, Health Savings Account, Health Reimbursement Account, or otherwise to a government or private payor. Ipsen reserves the right to rescind, revoke, or amend these offers without notice at any time. Ipsen and/or its copay assistance vendor are not responsible for any transactions processed under this program where Medicaid, Medicare, or Medigap payment in part or full has been applied. Data related to patient participation may be collected, analyzed, and shared with Ipsen for market research and other purposes related to assessing the program. Data shared with Ipsen will be de-identified, meaning it will not identify the patient. Void outside of the United States and its territories or where prohibited by law, taxed, or restricted. This program is not health insurance. No other purchase is necessary. Copay assistance cannot be sold, purchased, traded, or counterfeited. Void if reproduced.